Priya Kumthekar, MD
Enriched profileProfessor, Feinberg School of Medicine · Northwestern Medicine
Priya Kumthekar is Professor, Feinberg School of Medicine at Northwestern Medicine. OpenAlex indexes 450 publications with 6,971 citations (h-index 41); ClinicalTrials.gov lists 8 registered studies with this person as an investigator.
Data verified 23 Oct 2026
Overview
Updated 23 Oct 2026
Priya U. Kumthekar, MD, is Professor, Feinberg School of Medicine at Northwestern Medicine. The public record shows 450 publications with 6,971 citations (h-index 41), centered on Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 13 companies, 2 NIH-funded awards (2021–2026).
- Most recent indexed publication: 2026 · Cancers
- Top research focus: Glioma Diagnosis and Treatment
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 23 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 39 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 92.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 23 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer
Sponsor: Alliance for Clinical Trials in Oncology
- Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
Sponsor: Northwestern University
Industry payments
Updated 23 Oct 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SERVIER PHARMACEUTICALS LLCProgram year20255 payments
- Telix PharmaceuticalsProgram year20254 payments
- Deciphera Pharmaceuticals Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
52%Other antiepileptics52%Levetiracetam100%Part D<11 patientsMetabolism & gastrointestinal
48%Serotonin-3 Receptor Antagonist48%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 23 Oct 2026
2 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation
Northwestern University
FY2026$497,895R01CA272639 - A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation
Northwestern University
FY2025$598,126R01CA272639 - A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation
Northwestern University at Chicago
FY2024$568,219R01CA272639
Congress activity
Updated 23 Oct 2026
48 congress contributions (2014–2025) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Abstract 1784: Dynamic control of cerebrospinal fluid to achieve personalized drug delivery in the central nervous system
AACR Annual Meeting
AACR2025Presenting author - Abstract 4431: RRM2-driven dNTP biosynthesis: a therapeutic vulnerability in temozolomide-resistant glioblastoma
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 23 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205.
Clinical cancer research
Clinical Trial2026 - STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Journal of clinical oncology
Clinical Trial2026 - Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.
Nature medicine
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)Network
Updated 23 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 23 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/priya-kumthekar-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
nm.org/doctors/1649410036/priya-u-kumthekar-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →nm.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 23 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Board certified
American Board of Psychiatry and Neurology, Neurology
- Board certified
United Council for Neurologic Subspecialties, Neuro-Oncology
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →breakthroughsforphysicians.nm.org ↗
Media & interviews
press, podcasts and appearances- Healio Oncology Overdrive podcast
episode 39 (August 2021), "Applying Translational Oncology to Work-Life Integration"
2021provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cm.healio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bradley Knight, MD
Northwestern Medicine
Momen Wahidi, MD
Northwestern Medicine
Robin Buerki, MD
Northwestern Medicine
Vanessa Gates, MS, DABR, DABSNM
Northwestern Medicine
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
David Reardon, MD
Dana-Farber Cancer Institute